Schedule I posture on psilocybin and MDMA holds through 2026 with no DEA rescheduling action.

The DEA (US Drug Enforcement Administration) is the agency that decides which drugs sit on which federal restricted list. It won't move psilocybin or MDMA to a less restricted category in 2026 because no drug has been formally approved by the FDA (the US drug regulator) for those compounds — and that FDA approval is what normally triggers the DEA to reconsider. Without that trigger, nothing moves.

No completed FDA approval, no scheduling trigger. DEA does not move ahead of the science, and the docket confirms no pressure this year.